Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Dutogliptin Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. "Dutogliptin Market Size ...

SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus ...

Under the collaboration agreement, Forest will make an upfront payment of $75 million to Phenomix for the right to share dutogliptin expenses and profits, if the drug is approved. Phenomix could ...

SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) -- Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential ...

SAN FRANCISCO, May 18, 2020 /PRNewswire/ -- The article describes the evaluation of dutogliptin in healthy volunteers that preceded Recardio's ongoing Phase 2 safety and efficacy study in patients ...

SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- The clinical study is intended to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in ...

Medical research firm Recardio was due to try the drug dutogliptin on patients in Clydebank, Leeds and Exeter. It has suspended all UK activities due to uncertainty about how new medicines will be ...

Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post ...

Entitled “Randomized, Double Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction: rationale, design and ...

Trials for the drug dutogliptin, which were scheduled to be conducted on patients in Clydebank, Leeds and Exeter, were stopped by the company in an email sent Sept. 17, the BBC reported.

a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin.

US-based research firm Recardio was due to begin a study of the drug dutogliptin on patients in Exeter, Leeds and Clydebank. However, it has now suspended the UK arm of the trial over concerns ...